Royal Bank Of Canada Forecasts Strong Price Appreciation for Revvity (NYSE:RVTY) Stock

Key Points

• Royal Bank of Canada raised its Revvity price target to $172 from $135 but maintained a “sector perform” rating; the new target implies about 6.9% upside from the reported share price.
• Analyst views remain mixed: six rate the stock a Buy and 13 a Hold, with a MarketBeat average price target of $127.07.
• Revvity beat quarterly expectations, reporting adjusted EPS of $1.38 versus $1.30 expected and revenue of $728.9 million, up 4.3% year over year; the company also raised its 2026 outlook.

Revvity (NYSE:RVTY - Get Free Report) had its price target upped by Royal Bank Of Canada from $135.00 to $172.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a "sector perform" rating on the stock. Royal Bank Of Canada's target price suggests a potential upside of 6.86% from the company's current price.

A number of other equities analysts have also recently commented on RVTY. TD Cowen lifted their price target on Revvity from $130.00 to $175.00 and gave the stock a "buy" rating in a research note on Tuesday, October 13th. Barclays increased their price objective on Revvity from $115.00 to $160.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 7th. William Blair initiated coverage on shares of Revvity in a report on Monday, October 5th. They issued an "outperform" rating on the stock. Zacks Research raised shares of Revvity from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. Finally, Wall Street Zen lowered shares of Revvity from a "buy" rating to a "hold" rating in a report on Sunday, August 16th. Six investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to data from MarketBeat.com, Revvity currently has an average rating of "Hold" and an average price target of $127.07.

Revvity Trading Down 1.5%

Shares of NYSE:RVTY traded down $2.53 on Wednesday, reaching $160.95. 1,185,547 shares of the company traded hands, compared to its average volume of 1,533,872. The stock has a market capitalization of $17.96 billion, a P/E ratio of 76.48, a price-to-earnings-growth ratio of 2.76 and a beta of 1.08. The business's 50-day simple moving average is $145.89 and its 200 day simple moving average is $112.62. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. Revvity has a 52 week low of $81.22 and a 52 week high of $171.74.

Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $1.38 earnings per share for the quarter, beating analysts' consensus estimates of $1.30 by $0.08. The company had revenue of $728.90 million during the quarter, compared to analyst estimates of $694.73 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%. Revvity's revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.18 EPS. As a group, equities analysts anticipate that Revvity will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling at Revvity

In other news, insider Tajinder S. Vohra sold 7,330 shares of the firm's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the sale, the insider directly owned 6,635 shares of the company's stock, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Maxwell Krakowiak sold 1,631 shares of the firm's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the sale, the insider directly owned 14,781 shares of the company's stock, valued at approximately $2,136,297.93. This represents a 9.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 9,045 shares of company stock worth $1,281,439. 0.85% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Revvity

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jupiter Topco LLC bought a new stake in Revvity in the second quarter worth $961,017,000. BlackRock Inc. purchased a new stake in shares of Revvity in the second quarter worth $852,070,000. Wellington Management Group LLP boosted its stake in Revvity by 10,653.8% in the 2nd quarter. Wellington Management Group LLP now owns 865,575 shares of the company's stock worth $96,304,000 after purchasing an additional 857,526 shares in the last quarter. Primecap Management Co. CA bought a new position in Revvity in the 2nd quarter worth about $94,921,000. Finally, Bank of America Corp DE bought a new position in Revvity in the 2nd quarter worth about $87,116,000. Hedge funds and other institutional investors own 86.65% of the company's stock.

More Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported third-quarter adjusted EPS of $1.38, above analyst expectations of about $1.30, and revenue of $728.9 million, up 4.3% year over year and ahead of forecasts. Life Sciences strength and margin expansion helped drive results, and the company raised its 2026 outlook. Article: Q3 earnings beat on Life Sciences strength and 2026 outlook raised
• Positive Sentiment: CFRA upgraded RVTY from “hold” to “buy,” adding a favorable analyst signal following the results.
• Positive Sentiment: Coverage also pointed to AI-related demand and operational execution as contributors to broad-based growth, potentially supporting the company’s outlook. Article: Q3 deep dive on AI demand and operational execution
• Neutral Sentiment: Revvity reaffirmed its dividend, signaling continuity in its shareholder-return policy, though the announcement did not indicate an increase. Article: Revvity reaffirms its dividend
• Negative Sentiment: Some coverage questioned whether RVTY is now too pricey. Valuation concerns could limit further gains after the strong move following the earnings and guidance news. Article: Earnings beat and the case for Revvity stock

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.